Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
12 Agosto 2024 - 2:04PM
UK Regulatory
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members,
executives and associated persons
Bagsværd, Denmark, 12 August 2024 — This
company announcement discloses the data of the transaction(s) made
in Novo Nordisk shares by the company’s board members, executives
and their associated persons in accordance with Article 19 of
Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated
persons have reported the transactions to Novo Nordisk and have
given Novo Nordisk power of attorney on their behalf to publish
trading in Novo Nordisk shares by the company’s board members,
executives and their associated persons.
Please find below a statement of such trading in shares issued
by Novo Nordisk.
|
|
Details of the person discharging managerial
responsibilities/person closely associated |
|
a) |
Name of the Board member/Executive/Associated Person |
Mathilde Rantzau |
|
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Closely associated person to Thomas Rantzau, member of the Board of
Directors |
|
|
b) |
Initial notification/Amendment |
Initial notification |
|
|
3 |
Details of the issuer |
|
|
a) |
Name |
Novo Nordisk A/S |
|
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
|
4 |
Details of the transaction(s) |
|
|
a) |
Description of the financial instrument,
type of instrument, |
Shares
|
|
|
|
Identification code |
Novo Nordisk B DK0062498333 |
|
|
b) |
Nature of the transaction |
Purchase of shares |
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
DKK 891.20 |
11 shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
11 Shares
DKK 9,803.20 |
|
|
e) |
Date of the transaction |
2024-08-09 |
|
|
f) |
Place of the transaction |
Nasdaq Copenhagen |
|
Novo Nordisk is a leading global healthcare company, founded
in 1923 and headquartered in Denmark. Our purpose is to drive
change to defeat serious chronic diseases, built upon our heritage
in diabetes. We do so by pioneering scientific
breakthroughs, expanding access to our medicines and working to
prevent and ultimately cure disease. Novo Nordisk
employs about 69,000 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the
New York Stock Exchange (NVO). For more
information, visit novonordisk.com,
Facebook, Instagram,
X, LinkedIn and
YouTube.
Contacts for further information
|
Media: |
|
Ambre
James-Brown
+45 3079 9289
abmo@novonordisk.com
|
Liz
Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com |
|
Investors: |
|
Jacob
Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com
|
David
Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com
|
Sina
Meyer
+45 3079 6656 azey@novonordisk.com
|
Mark
Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com
|
Ida Schaap
Melvold
+45 3077 5649
idmg@novonordisk.com |
Frederik
Taylor Pitter
+45 3075 8259 fptr@novonordisk.com |
Company announcement No 61 / 2024
Grafico Azioni Novo Nordisk (TG:NOV)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Novo Nordisk (TG:NOV)
Storico
Da Dic 2023 a Dic 2024
